Canada - English - Health Canada

dominion pharmacal - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Canada - English - Health Canada

dominion pharmacal - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

Canada - English - Health Canada

aa pharma inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Canada - English - Health Canada

aa pharma inc - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - bromocriptine mesilate - oral tablet - 2.5mg

Singapore - English - HSA (Health Sciences Authority)

pharmaforte singapore pte ltd - bromocriptine mesylate eqv bromocriptine - tablet, film coated - 2.5 mg - bromocriptine mesylate eqv bromocriptine 2.5 mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

United States - English - NLM (National Library of Medicine)

veroscience llc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - women who are nursing their children. cycloset may inhibit lactation. there are postmarketing reports of stroke in this patient population although causality has not been proven [see use in specific popu

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - bromocriptine mesylate - tablet - each tablet contains bromocriptine mesylate equivalent to bromocriptine 2,5 mg

Canada - English - Health Canada

pro doc limitee - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists